Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of the contract. This follows the licence granted to Emergex from Midatech Pharma, which was announced in January this year.
This author has not written his bio yet.
But we are proud to say that gatekeeper contributed 31 entries already.
Entries by gatekeeper
© EMERGEX VACCINES
Website maintained by Digital Trading